VEGFA and hepatocellular carcinoma: Recently, the use of atezolizumab plus bevacizumab, a combination of immune checkpoint inhibitors and vascular endothelial growth factor antibodies, has significantly improved the prognosis of unresectable HCC compared to sorafenib [7,8]; therefore, an atezolizumab plus bevacizumab combinatorial treatment has been approved as a first-line systemic chemotherapy for unresectable HCC worldwide [3,9,10,11].